Industry Overview
Operates within the rapidly expanding digital health, wellness and consumer subscription technology market, delivering personalised health optimisation programmes through artificial intelligence.
Business Description
Proprietary iOS and Android platform offering programmes across anti-alcohol, anti-vaping, testosterone optimisation and high-performance wellness. The technology is hosted on AWS, localised into more than ten languages and supported by a full in-house team.ay 2026.
Financial Summary
TTM net sales are USD 12.7 million, with EBITDA of USD 1.1 million and monthly recurring revenue of approximately USD 1.3 million. Forecast TTM sales are USD 24.8 million, with forecast EBITDA of USD 2.4 million. The business generated over USD 300,000 EBITDA in May 2026.
Investment Rationale
Market-leading App Store position, recurring subscription revenues, proprietary AI technology, owned source code and significant international and product expansion potential.
Customer Overview
Global B2C audience supported by 4.3 million email subscribers and approximately 800,000 Instagram followers.
Transaction Information
Full business sale with an asking price of USD 10 million. The founder seeks a clean exit, while the existing operating team will remain following completion.
To register interest you will need to complete our Buyer Verification Process.
